Segment 9. Experts discuss the effect of preservatives in topical medications on the ocular surface and newer agents like bimatoprost SR to overcome these limitations.
Segment 8. Emergence of minimally invasive glaucoma surgeries as an alternative for non-adherent patients.
Segment 7. Sahar Bedrood, MD, PhD, reveals how she addresses issues related to adherence with patients and the importance of lifestyle management.
Segment 6. Joseph Panarelli, MD, explains the role of MMPs in OAG and development of other modalities to treat open-angle glaucoma.
Segment 5. Key opinion leaders discuss an emerging pharmacotherapeutic in the treatment of open-angle glaucoma.
Segment 4. Expert leaders review the recently approved pharmacotherapeutics to treat open-angle glaucoma along with their safety and efficacy profile.
Segment 3. Importance of monitoring IOP fluctuations and the associated risk for visual field loss.
Segment 2. Joseph Panarelli, MD, reviews the available topical treatment landscape for the management of open-angle glaucoma.
Segment 1. Sahar Bedrood, MD, PhD, provides an overview on the role of IOP in open-angle glaucoma and parameters that contribute to IOP.